Cytel Has Partnered With New Mountain Capital
November 2, 2017
Cytel, Inc. (“Cytel”) the leading global provider of innovative analytical software and services to the life sciences industry, today announced that it has partnered with New Mountain Capital, LLC (“New Mountain”).
Cain Brothers served as financial advisor to Cytel in connection with the transaction.
Headquartered in Cambridge, MA, Cytel is widely recognized as an industry pioneer of adaptive clinical trials and a thought leader in statistical science. Cytel’s software and outsourced services are used by over 400 life sciences customers, including all of the world’s 30 largest pharmaceutical companies, as well as regulatory bodies such as the FDA. Through a combination of clinical trial software solutions, consulting services, and specialized resources, Cytel helps its customers to improve decision-making and reduce risk across the drug product lifecycle, increase R&D productivity and further medical innovation.
New Mountain Capital is a New York based investment firm focused on long-term business-building and growth investments. The firm currently manages private equity, public equity, and credit funds with over $20 billion in assets under management. New Mountain seeks out what it believes to be the highest quality growth leaders in carefully selected industry sectors and then works intensively with management to build the value of these companies.